Baseline value ($) | Range ($) | Distribution | Reference | |
---|---|---|---|---|
Durvalumab | 7,866.6/ 1,500 mg | 5,899.95–9,833.25 | lognormal | [20] |
Atezolizumab | 4,755/1,200 mg | 3,566.25–5,943.75 | lognormal | [20] |
Pembrolizumab | 2,612.83/100 mg | 1,959.69–3,266.11 | lognormal | [27] |
Nivolumab | 665/40 mg | 498.75–831.25 | lognormal | [20] |
Ipilimumab | 81.2/mg | 60.9–101.5 | lognormal | [20] |
Sintilimab | 157.5/100 mg | 118.13–196.88 | lognormal | [28] |
Camrelizumab | 426.9/200 mg | 320.2–533.7 | lognormal | |
Tislelizumab | 317.89/100 mg | 238.42–397.36 | lognormal | [31] |
Bevacizumab | 262.5/100 mg | 196.88–328.13 | lognormal | [32] |
Tremelimumaba | 81.2/mg | 60.9–101.5 | lognormal | - |
Carboplatin | 0.16/mg | 0.12–0.21 | lognormal | [27] |
Pemetrexed | 131.24/100 mg | 98.43–164.05 | lognormal | [32] |
Docetaxel | 189.57/200 mg | 142.18–236.96 | lognormal | [33] |
Cost of medical service of immunotherapy per cycle | 8.20 | 6.15–10.25 | lognormal | [27] |
Cost of medical service of chemotherapy per cycle | 45.97 | 34.48–57.47 | lognormal | [27] |
Follow-up cost per cycle | 58.53 | 43.90–73.17 | lognormal | |
Utility for PFS | 0.804 | 0.683–0.925 | beta | [35] |
Utility for PD | 0.321 | 0.273–0.369 | beta | [35] |
Utility for death | 0 | 0 | - | - |
Discount rate | 5% | 0–8% | - | [25] |